|Company Profile about Human Growth Hormone (HGH)|
I. Establishment and Development
In 2004, Zhongshan Hygene Biopharm Co., Ltd., (originally known as Shanghai Hygene Biopharm Co., Ltd.) was set up in Zhongshan National Health Base with registered capital of RMB 5 billion. The business scopes include the production and sales of genetic recombination products (recombinant human growth hormone for injection), as well as research of biological products.
In July 2005, Zhongshan Hygene Biopharm Co., Ltd. took about one year to complete the overall construction of the modernized factory. The company has 1270㎡ administrative offices and 1620㎡ all-in-one workshop which are in accordance with the requirements of GMP standard. It has established and improved the production and operation management system and won the Certificate of Pharmaceutical GMP and the Drug Production License issued by the State Food and Drug Administration Authority and formally put into production.
In May 2006, the company was credited with the honor of Guangdong Hi-tech Enterprise
In November 2006, the company won the certificate of Guangdong Private Technology Enterprise.
Ever since the production operation was in practice, the company has achieved a remarkable business performance in recent years and it becomes a rising star of China's biopharmaceutical industry.
The company continues its investment in R&D and piloting test of genetic engineering drugs in the past years. Actually the company has been experiencing business success for industrial and commercial operation for almost two decades with the accumulation technology know how and business management wisdom. The new slogan of the company is Three Heights and One Length (high input, high-risk, high-yield, long-cycle) further lead the business into the high-growing phase of the enterprise.
II. Product - Hygetropin® human growth hormone (HGH)
The company's main product --"Hygetropin"—is a kind of gene recombinant protein drug and its registered trade mark is “Recombinant Human Somatropin for Injection”. The product is classified as the second category of new drugs of the country and with independent intellectual property rights. Product specifications include 2.5IU / bottle, 4IU / bottle and 8IU / bottle. They have been certified with Drug Approval Permit No. and pharmaceutical production license issued by the State Food and Drug Administration the PRC in 2005.
The growth hormone is a kind of peptide hormone secreted by anterior pituitary (adenohypophysis), and human pituitary weighs about 0.5g, with a minimal amount of growth hormone. In 1955, the human growth hormone (HGH), which consists of 191 single-chain peptide of amino acids, was isolated from human pituitary for the first time. 24 years later, the first human growth hormone (HGH) gene was cloned for the first time.
The main physiological role of human growth hormone (HGH)is to promote the growth and development, and its receptors are distributed throughout all the tissues of the body. The main physiological functions of growth hormone are to promote the growth of cartilages, bones and cells, repair tissues and regulate metabolism. Its clinical applications are mainly reflected in five aspects: clinical short stature, clinical postoperative, anti-aging, clinical reproductive and clinical burning.
Hygetropin® human growth hormone (HGH) is a gene recombinant protein drug composed of 191 amino acids, completely identical with natural human growth hormone in structure, having the same efficacy and having no adverse effects.